Skip to main content

Table 2 Odd Ratio and Goodness of Fit for Sequential Models of Mortality Predictions of ADR events

From: Development of a mortality score to assess risk of adverse drug reactions among hospitalized patients with moderate to severe chronic kidney disease

Variable Models
1
Comorbidities
2
Comorbidities +
Type of Medication
3
Comorbidities +
Type of Medication +
Lab Results
4
Comorbidities +
Type of Medication +
Lab Results +
Total Medication Use
5
Comorbidities +
Type of Medication +
Lab Results +
Total Medication Use +
Renal Replacement Therapy
a Heart Disease 0.44 (0.18–1.08) 0.44 (0.17–1.15) 0.43 (0.16–1.15) 0.42 (0.15–1.19) 0.46 (0.16–1.32)
Dyslipidaemia 0.32 (0.13–0.84) 0.25 (0.09–0.70) 0.21 (0.07–0.64) 0.24 (0.08–0.73) 0.23 (0.07–0.71)
b Electrolyte Disorder 3.56 (1.19–10.70) 6.36 (1.92–21.08) 5.79 (1.70–19.77) 5.31 (1.49–18.88) 5.72 (1.57–20.89)
c Psychotic Agents   9.42 (3.04–29.12) 8.78 (2.68–28.81) 6.13 (1.77–21.26) 6.02 (1.76–20.64)
Creatinine Kinase ≥171 U/L    6.72 (1.70–26.52) 7.68 (1.75–33.66) 6.81 (1.49–31.20)
≥ 23 No. medications     4.27 (1.49–12.24) 4.66 (1.58–13.79)
Conservative management      1.59 (0.55–4.66)
Hosmer and Lemeshow Test 0.418 0.860 0.623 0.899 0.643
Nagelkerke R Square 0.127 0.267 0.329 0.393 0.399
p value 0.005 < 0.001 < 0.001 < 0.001 < 0.001
  1. Abbreviation: GFR, glomerular filtration rate
  2. Data are presented as odd ratios (95% confidence interval) unless otherwise stated
  3. aHeart Disease is defined as presence of vascular or/and heart failure aetiology
  4. bElectrolyte Disorder is defined as presence of hypokalaemia or hyperkalaemia
  5. cPsychrotic Agents is defined as drugs that are classified as psychotropic drugs
  6. dSI conversion: To convert Creatinine kinase to μkat/L, multiply by 58.82